Stefaan Van Gool MD. PhD.
Medical Director of Translational Oncology at the IOZK
Tumor immunologist with a focus on brain tumors
Stefan Van Gool MD. PhD, is a specialist in pediatric hemato-oncology with a focus on brain tumors. From 2001 to 2004 he was head of clinical research at the Fund for Scientific Research Flanders. Between 2006 and 2016, he was a professor at the Faculty of Medicine of the Catholic University of Leuven. From 2012 to 2015 he was head of the Laboratory of Pediatric Immunology. He is the author of almost 200 scientific articles in international scientific journals.
In recognition of his scientific achievements, he received the following awards:
1995 Schweißguth Prize of the International Society of Pediatric Oncology
1996 Nycomed Prize of the International Society of Paediatric Oncology
1998 Prize for cancer research from the Rik en Nel Wouters Foundation (with Ludwig Van den Hove)
Between 2005 and 2009, he was coordinator of the European Expert Group on High Grade Glioma
He has been a member of the High Health Council in Belgium since 2008
From 2014 to 2017, he was co-chair of the brain tumor working group of the European Society for Paediatric Oncology
At the IOZK, he is medical director and responsible for the planning and implementation of IOZK immunotherapy. He is a Qualified Person (GMP) for the manufacture of medicinal products
"Since every tumor is different, the best results are achieved by targeting the unique set of tumor cells with the patient's own dendritic cells"
Stefaan Van Gool MD. PhD.
Collection: Scientific contributions and international publications by Stefaan Van Gool MD. PhD
Further information on this topic:
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
The Complexity of Malignant Glioma Treatment
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
The Application of Evidence-Based Medicine in Individualized Medicine
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
Stefaan van Gool is editor of a special issue in the Journal of Molecular Sciences
Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
Poster presentation at the annual meeting of the Association for Cancer Immunotherapy
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival
Impaired DNA repair in mouse monocytes compared to macrophages and precursors
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
IOZK analysis proves good tolerability of IOZK immunotherapy in diffuse intrinsic pontine glioma (DIPG)
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
Symposium & advanced training at the IOZK: Immunotherapy in neuro-oncology, Fri. 06.09.2019
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group
IOZK article on treatment trials for glioblastoma in the specialist journal: "Austin Oncology Case Report"
IOZK lecture: Modulated electro-hyperthermia in children with DIPG, ESHO conference, Charité Berlin
IOZK lecture on the effects of multimodal immunotherapy for pons glioma using the liquid biopsy analysis method.
IOZK lecture by Stefaan Van Gool: IOZK Immunotherapy for DIPG Ponsglioma, Society for Neuro-Oncology Conference, San Francisco
Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival
Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade
Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy
IOZK article in Austin Oncology Case Reports on cancer vaccines
Article about Stefaan Van Gool as a pediatric neuro-oncologist in the Washington Post
Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease
Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group
Publication by Stefaan Van Gool MD. PhD: Electroporation of Dendritic Cells with WT1, Survivin, and TriMix
IOZK article in the journal for orthomolecular medicine, special issue: Oncology
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma
Stefaan Van Gool moves from the University of Leuven to the IOZK
Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
Brain Tumor Immunotherapy: What have We Learned so Far?
Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies
Myeloid-derived suppressor cells in glioma
Dendritic cell-based immunotherapy in ovarian cancer
Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours
Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination
Dendritic cell therapy of high-grade gliomas
Vaccine therapy in patients with renal cell carcinoma
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells
Dendritic cell vaccination in patients with malignant gliomas: current status and future directions
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report